|
Sep 16
|
Nuvalent Announces Public Offering of Common Stock
|
|
Sep 14
|
Nuvalent, Inc. (NUVL): Among Hedge Funds’ Top Biotech Stock Picks
|
|
Sep 14
|
Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock
|
|
Sep 14
|
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
|
|
Sep 13
|
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655
|
|
May 9
|
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
|
|
May 8
|
Why Earnings Season Could Be Great for Nuvalent (NUVL)
|
|
Apr 8
|
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
|
|
Apr 5
|
Chief Legal Officer Deborah Miller Sells 3,000 Shares of Nuvalent Inc (NUVL)
|
|
Apr 5
|
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
|
|
Mar 29
|
Chief Legal Officer Deborah Miller Sells 22,000 Shares of Nuvalent Inc (NUVL)
|
|
Mar 25
|
Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL)
|
|
Mar 22
|
Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth
|
|
Mar 19
|
Director Emily Conley Sells 13,333 Shares of Nuvalent Inc (NUVL)
|
|
Mar 5
|
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
|
|
Feb 12
|
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors
|
|
Jan 8
|
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones
|
|
Jan 1
|
Nuvalent, Inc. (NASDAQ:NUVL) Shares Could Be 35% Below Their Intrinsic Value Estimate
|
|
Dec 22
|
Director Anna Protopapas Sells 5,000 Shares of Nuvalent Inc (NUVL)
|
|
Dec 21
|
Chief Development Officer Darlene Noci Sells 40,000 Shares of Nuvalent Inc (NUVL)
|